Imre Noth

List of Publications by Citations

108 papers	6,950 citations	39 h-index	83 g-index
140 ext. papers	8,905 ext. citations	10.4 avg, IF	5.42 L-index

#	Paper	IF	Citations
108	Acute exacerbations of idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 176, 636-43	10.2	823
107	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. *European Respiratory Journal*, **2015**, 46, 976-87	13.6	541
106	A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 88-95	10.2	350
105	Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. *Lancet Respiratory Medicine,the*, **2013**, 1, 309-317	35.1	341
104	Churg-Strauss syndrome. *Lancet, The*, **2003**, 361, 587-94	40	299
103	Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. *JAMA - Journal of the American Medical Association*, **2013**, 309, 2232-9	27.4	286
102	Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. *Lancet Respiratory Medicine,the*, **2013**, 1, 369-76	35.1	276
101	Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. *Lancet Respiratory Medicine,the*, **2014**, 2, 548-56	35.1	252
100	Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. *JAMA Oncology*, **2017**, 3, 636-651	13.4	236
99	Autoimmune-featured interstitial lung disease: a distinct entity. *Chest*, **2011**, 140, 1292-1299	5.3	193
98	TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 1475-82	10.2	187
97	Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. *Science Translational Medicine*, **2013**, 5, 205ra136	17.5	170
96	Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 214-22	10.2	159
95	Characterisation of patients with interstitial pneumonia with autoimmune features. *European Respiratory Journal*, **2016**, 47, 1767-75	13.6	159
94	A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. *New England Journal of Medicine*, **2011**, 364, 1576-7	59.2	157
93	Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. *Lancet Respiratory Medicine,the*, **2014**, 2, 557-65	35.1	151
92	Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. *Lancet Respiratory Medicine,the*, **2017**, 5, 869-880	35.1	142

91	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 1036-1044	10.2	109
90	PD-1 up-regulation on CD4 T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-1 production. *Science Translational Medicine*, **2018**, 10,	17.5	109
89	Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 208-219	10.2	89
88	Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 564-574	10.2	81
87	Peripheral blood biomarkers in idiopathic pulmonary fibrosis. *Translational Research*, **2012**, 159, 218-27	11	80
86	Recent advances in idiopathic pulmonary fibrosis. *Chest*, **2007**, 132, 637-50	5.3	79
85	Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. *Lancet Respiratory Medicine,the*, **2018**, 6, 707-714	35.1	74
84	Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis. *FASEB Journal*, **2013**, 27, 1749-60	0.9	67
83	Telomere length and genetic variant associations with interstitial lung disease progression and survival. *European Respiratory Journal*, **2019**, 53,	13.6	67
82	Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. *Lancet Respiratory Medicine,the*, **2017**, 5, 857-868	35.1	59
81	Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. *Respiratory Medicine*, **2016**, 121, 117-122	4.6	57
80	Peripheral blood gene expression as a novel genomic biomarker in complicated sarcoidosis. *PLoS ONE*, **2012**, 7, e44818	3.7	54
79	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 199-208	10.2	53
78	CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Disease-Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. *American Journal of Roentgenology*, **2018**, 210, 307-313	5.4	53
77	Association between MUC5B and TERT polymorphisms and different interstitial lung disease phenotypes. *Translational Research*, **2014**, 163, 494-502	11	50
76	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. *Chest*, **2018**, 153, 94-104	5.3	47
75	Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2015**, 45, 1393-402	13.6	46
74	Sphingosine-1-phosphate lyase is an endogenous suppressor of pulmonary fibrosis: role of S1P signalling and autophagy. *Thorax*, **2015**, 70, 1138-48	7.3	46

73	Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. *ERJ Open Research*, **2017**, 3,	3.5	46
72	Rare Protein-Altering Telomere-related Gene Variants in Patients with Chronic Hypersensitivity Pneumonitis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1154-1163	10.2	45
71	Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 336-347	10.2	41
70	Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases. *Annals of the American Thoracic Society*, **2019**, 16, 580-588	4.7	41
69	The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. *PLoS ONE*, **2011**, 6, e14715	3.7	39
68	CT Findings, Radiologic-Pathologic Correlation, and Imaging Predictors of Survival for Patients With Interstitial Pneumonia With Autoimmune Features. *American Journal of Roentgenology*, **2017**, 208, 1229-1236	5.4	37
67	Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1402-1413	10.2	37
66	Thyroid Disease Is Prevalent and Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. *Chest*, **2015**, 148, 692-700	5.3	36
65	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. *Lancet Respiratory Medicine,the*, **2019**, 7, 771-779	35.1	34
64	The mitochondrial cardiolipin remodeling enzyme lysocardiolipin acyltransferase is a novel target in pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 1402-15	10.2	31
63	The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes. *Scientific Reports*, **2017**, 7, 46560	4.9	28
62	Idiopathic pulmonary fibrosis: early detection and referral. *Respiratory Medicine*, **2014**, 108, 819-29	4.6	27
61	A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. *BMC Pulmonary Medicine*, **2015**, 15, 147	3.5	27
60	Interstitial lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment. *Arquivos De Gastroenterologia*, **2011**, 48, 91-7	1.3	27
59	Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort. *Chest*, **2018**, 153, 349-360	5.3	26
58	CT findings associated with survival in chronic hypersensitivity pneumonitis. *European Radiology*, **2017**, 27, 5127-5135	8	25
57	Pathologic quantification of connective tissue disease-associated versus idiopathic usual interstitial pneumonia. *Archives of Pathology and Laboratory Medicine*, **2012**, 136, 1253-8	5	25
56	Interstitial Pneumonia With Autoimmune Features: Value of Histopathology. *Archives of Pathology and Laboratory Medicine*, **2017**, 141, 960-969	5	22

55	Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 747-759	10.2	22
54	Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. *Chest*, **2019**, 156, 706-714	5.3	21
53	Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. *BMC Pulmonary Medicine*, **2020**, 20, 64	3.5	21
52	Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA. *European Respiratory Journal*, **2018**, 52,	13.6	20
51	Skewed Lung CCR4 to CCR6 CD4 T Cell Ratio in Idiopathic Pulmonary Fibrosis Is Associated with Pulmonary Function. *Frontiers in Immunology*, **2016**, 7, 516	8.4	19
50	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. *Chest*, **2020**, 157, 1506-1512	5.3	18
49	CT-Pathologic Correlation of Major Types of Pulmonary Fibrosis: Insights for Revisions to Current Guidelines. *American Journal of Roentgenology*, **2018**, 210, 1034-1041	5.4	17
48	Integrating Genomics Into Management of Fibrotic Interstitial Lung Disease. *Chest*, **2019**, 155, 1026-1040	5.3	16
47	African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis. *European Respiratory Journal*, **2018**, 51,	13.6	16
46	Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. *European Respiratory Journal*, **2019**, 54,	13.6	16
45	Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial. *Respiratory Research*, **2020**, 21, 68	7.3	15
44	Novel idiopathic pulmonary fibrosis susceptibility variants revealed by deep sequencing. *ERJ Open Research*, **2019**, 5,	3.5	14
43	Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 250-253	10.2	14
42	Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK trial. *BMJ Open Respiratory Research*, **2018**, 5, e000325	5.6	13
41	N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open. *Lancet Respiratory Medicine,the*, **2017**, 5, e1-e2	35.1	12
40	Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 325, 1841-1851	27.4	12
39	Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. *Chest*, **2020**, 158, 1526-1534	5.3	11
38	Sepsis-associated acute respiratory distress syndrome in individuals of European ancestry: a genome-wide association study. *Lancet Respiratory Medicine,the*, **2020**, 8, 258-266	35.1	10

37	Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. *Scientific Reports*, **2019**, 9, 14802	4.9	10
36	Expression profiling elucidates a molecular gene signature for pulmonary hypertension in sarcoidosis. *Pulmonary Circulation*, **2016**, 6, 465-471	2.7	9
35	Genetics of Idiopathic Pulmonary Fibrosis. *American Journal of the Medical Sciences*, **2019**, 357, 379-383	2.2	8
34	The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. *Annals of the American Thoracic Society*, **2020**, 17, 1620-1628	4.7	8
33	Pharmacogenetics and interstitial lung disease. *Current Opinion in Pulmonary Medicine*, **2016**, 22, 456-65	3	8
32	Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin? : a reply to Tzouvelekis. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 214	10.2	7
31	Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. *European Respiratory Journal*, **2021**, 57,	13.6	7
30	Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, 197-208	10.2	7
29	Autoimmune Hypothyroidism As a Predictor of Mortality in Chronic Hypersensitivity Pneumonitis. *Frontiers in Medicine*, **2017**, 4, 170	4.9	6
28	Myositis-specific Antibodies Identify A Distinct Interstitial Pneumonia with Autoimmune Features Phenotype. *European Respiratory Journal*, **2020**,	13.6	6
27	Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 458-470	10.2	6
26	Reply: Is Warfarin the Right Anticoagulant in Idiopathic Pulmonary Fibrosis?. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 693-694	10.2	4
25	Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative. *Chest*, **2021**,	5.3	4
24	Proportion of Idiopathic Pulmonary Fibrosis Risk Explained by Known Common Genetic Loci in European Populations. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 775-778	10.2	4
23	N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia. *BMC Pulmonary Medicine*, **2018**, 18, 30	3.5	3
22	CPAP Adherence, Mortality, and Progression-Free Survival in Interstitial Lung Disease and OSA. *Chest*, **2020**, 158, 1701-1712	5.3	3
21	Automated CT Analysis of Major Forms of Interstitial Lung Disease. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
20	Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF. *JCI Insight*, **2021**, 6,	9.9	3

19	GERD and idiopathic pulmonary fibrosis: cause or effect. *Current Respiratory Care Reports*, **2013**, 2, 260-267		2
18	Reply: A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup?. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 1030	10.2	2
17	Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. *European Respiratory Journal*, **2021**, 58,	13.6	2
16	Reply: rationale for anticoagulant therapy of pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 363	10.2	1
15	Interstitial Lung Disease and Antinuclear Antibody: Response. *Chest*, **2012**, 141, 1361	5.3	1
14	Associations of D-Dimer with Computed Tomographic Lung Abnormalities, Serum Biomarkers of Lung Injury, and Forced Vital Capacity: MESA Lung Study. *Annals of the American Thoracic Society*, **2021**, 18, 1839-1848	4.7	1
13	Anti-RNA binding protein positivity in idiopathic interstitial pneumonia. *Respiratory Medicine*, **2019**, 146, 23-27	4.6	1
12	MicroRNA and protein-coding gene expression analysis in idiopathic pulmonary fibrosis yields novel biomarker signatures associated to survival. *Translational Research*, **2021**, 228, 1-12	11	1
11	50-gene risk profiles in peripheral blood predict COVID-19 outcomes: A retrospective, multicenter cohort study. *EBioMedicine*, **2021**, 69, 103439	8.8	1
10	T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival. *Respiratory Medicine: X*, **2019**, 1, 100002-100002	1.6	0
9	Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort.. *Lung*, **2022**, 200, 11	2.9	0
8	Radiomics-based assessment of idiopathic pulmonary fibrosis is associated with genetic mutations and patient survival. *Journal of Medical Imaging*, **2021**, 8, 031903	2.6	0
7	Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis		0
6	Response. *Chest*, **2016**, 149, 600-601	5.3	
5	Genesis of Some Histologic, BAL, and Auscultatory Features of Idiopathic Pulmonary Fibrosis. *Chest*, **2008**, 133, 585-586	5.3	
4	Gastroesophageal Reflux and IPF **2014**, 281-296		
3	When Is It More Than Just a Spicy Meal?. *Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A*, **2016**, 26, 499-500	2.1	
2	Reply to Lescoat et al. and to Khamis et al. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 1041-1042	10.2	

1	Antimicrobial Therapy and Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis-Reply. *JAMA - Journal of the American Medical Association*, **2021**, 326, 1071-1072	27.4